Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT03931109 Recruiting - Clinical trials for Osteoporosis, Postmenopausal

Circulating miRNA in Primary Hyperparathyroidism

Start date: September 7, 2018
Phase:
Study type: Observational [Patient Registry]

The goal of this study is to: 1. Analyze the expression levels of circulating (serum) miRNAs in primary hyperparathyroidism patients with and without osteoporosis, and patients with osteoporosis undergoing thyroidectomy, and to correlate with clinical markers of bone remodeling including biochemical and radiologic studies. 2. To evaluate serum miRNA levels after treatment with parathyroidectomy.

NCT ID: NCT03930992 Recruiting - Clinical trials for Secondary Osteoporosis

Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men

OSZCO
Start date: April 17, 2019
Phase: Phase 3
Study type: Interventional

Clinical trial to assess the effectiveness of the supplement Colaren® associated with zoledronic acid 4mg/annually in the treatment of osteoporosis secondary, compared to standard treatment plus zoledronic acid 4mg/annually. The standard treatment will include 1gr of calcium/day and vitamin D supplement. In both cases, vitamin D levels will be determinated, which should remain at more than 30 ng/mL. Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism, bone formation and bone resorption will be assessment. The all parameters above will be assessed basally (before the start of treatment), after starting the treatment, an assessment will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile, at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned above will be measured.

NCT ID: NCT03930758 Completed - Clinical trials for Diabetes Mellitus, Type 2

Preventing Diabetic Osteoporosis With Exercise

DIABETICBONE
Start date: October 8, 2009
Phase: N/A
Study type: Interventional

The two specific aims of the study were to determine whether: 1. Greater mechanical loading of downhill exercise will increase the osteogenic index (ratio between CICP, the marker of bone formation (c-terminal propeptide of type I collagen, and CTX, the marker of bone resorption (c terminal telopeptide of type I collagen)) to a greater extent than uphill exercise that provides lower ground-reaction force; 2. Exercise after the meals will induce greater osteogenic response than exercise pefore the meals as it is known that meal eating during daytime inhibits bvone resorption markers.

NCT ID: NCT03926377 Not yet recruiting - Osteoporosis Clinical Trials

Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid

DERMOS
Start date: April 2019
Phase: Phase 4
Study type: Interventional

Bullous pemphigoid is the most common type of bullous skin disease and is clinically characterized by clear-tense bullae, which result in post-bullous cutaneous erosions, altering the skin barrier. The treatment of this pathology consists of the application of high doses of topical corticosteroids (clobetasol propionate) for a prolonged period of at least 6 months. The main objective of this study is to demonstrate a change in bone mineral density at 6 months after initiation of treatment, in subjects with bullous pemphigoid and treated with topical corticosteroid.

NCT ID: NCT03925532 Not yet recruiting - Osteoporosis Clinical Trials

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Start date: August 1, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant. Patients receiving a donor stem cell transplant may experience accelerated bone loss and an increase risk of bone fractures, leading to a decrease in satisfaction and quality of life. A type of immunotherapy drug called denosumab binds to a protein called RANKL, which may help keep bone from breaking down.

NCT ID: NCT03925051 Not yet recruiting - Clinical trials for Postmenopausal Osteoporosis

Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers

Start date: May 21, 2019
Phase: Phase 1
Study type: Interventional

CMAB807 is a human monoclonal antibody targeting the key bone resorption mediator RANKL. The drug is administered via subcutaneous injection once six months and is approved for various indications, including the treatment of postmenopausal women with osteoporosis at increased/high risk of fracture. This phase 1 clincical study investigates the pharmacokinetics, safety and immnogenicity of CMAB807,compared to prolia®, in healthy Chinese male subjects.

NCT ID: NCT03924414 Not yet recruiting - Parkinson Disease Clinical Trials

Trial of Parkinson's And Zoledronic Acid

TOPAZ
Start date: June 1, 2019
Phase: Phase 4
Study type: Interventional

This study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 65 years and older with Parkinson's Disease with 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

NCT ID: NCT03921060 Not yet recruiting - Cystic Fibrosis Clinical Trials

Markers of Osteoporosis in Cystic Fibrosis

Start date: July 2019
Phase: Phase 4
Study type: Interventional

Main Study Up to 100 subjects, both non-CF volunteers and Cystic Fibrosis (CF) patients, will participate in a single study visit that will include a DEXA scan, micro CT, and blood collection. Denosumab (Prolia) Sub study Approximately 50 adult subjects with CF who participated in the main study and have results indicating bone disease will receive treatment with Denosumab for up to 5 years. They will be asked to return annually for repeat DEXA scans, micro CT, and blood collection.

NCT ID: NCT03916289 Recruiting - Osteoporosis Clinical Trials

A Tiered Management System of Osteoporosis in China

Start date: November 1, 2018
Phase:
Study type: Observational [Patient Registry]

There is a management gap in China. This study aims to establish a tiered management system of osteoporosis for Chinese patients. Including: 1. Developing a national hierarchical health management network platform for middle-aged and elderly osteoporosis patients. With this platform, the data of medical records, laboratory results would be shared between medical institutions. And primary hospitals can refer the patients to the nearest medical centre for advanced auxiliary examinations and diagnosis. 2. Establishing a muti-level hospital collaboration, doctor-patient interaction management model of osteoporosis. 3. To explore and establish a early warning and screening pathways for osteoporosis.

NCT ID: NCT03910348 Completed - Clinical trials for Osteoporosis, Postmenopausal

Effects of Whole-Body Vibration and High Impact Exercises in Postmenopausal Women

Start date: January 2010
Phase: N/A
Study type: Interventional

We investigated the effects of whole body vibration (WBV) and high-impact (HI) exercises in postmenopausal women with low bone mineral density. In summary, WBV exercises are effective in preventing bone loss and WBV and HI exercise programs are effective in decreasing fall risk, increasing health-related quality of life and improving depressive symptoms